Dermira (NASDAQ:DERM) Sees Unusually-High Trading Volume

Dermira Inc (NASDAQ:DERM) shares saw strong trading volume on Friday . 8,523,845 shares changed hands during trading, an increase of 591% from the previous session’s volume of 1,234,328 shares.The stock last traded at $8.23 and had previously closed at $6.97.

A number of equities research analysts have weighed in on the company. Zacks Investment Research raised Dermira from a “hold” rating to a “strong-buy” rating and set a $6.50 price objective on the stock in a report on Wednesday, October 9th. BidaskClub raised Dermira from a “strong sell” rating to a “sell” rating in a report on Saturday, October 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Dermira in a report on Friday, October 18th. Finally, Leerink Swann decreased their price objective on Dermira from $23.00 to $15.00 and set an “outperform” rating on the stock in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Dermira has a consensus rating of “Buy” and an average price target of $17.12.

The company has a quick ratio of 8.08, a current ratio of 8.42 and a debt-to-equity ratio of 4.95. The business has a fifty day simple moving average of $6.66 and a two-hundred day simple moving average of $8.60. The company has a market capitalization of $368.00 million, a price-to-earnings ratio of -1.57 and a beta of 1.33.

Dermira (NASDAQ:DERM) last released its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.40) by $0.34. Dermira had a negative return on equity of 485.60% and a negative net margin of 256.08%. The company had revenue of $11.53 million for the quarter, compared to the consensus estimate of $11.07 million. As a group, equities analysts predict that Dermira Inc will post -4.42 earnings per share for the current fiscal year.

In other news, CEO Thomas G. Wiggans bought 23,419 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was bought at an average price of $8.54 per share, for a total transaction of $199,998.26. Following the completion of the purchase, the chief executive officer now owns 39,666 shares of the company’s stock, valued at approximately $338,747.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Matthew K. Fust sold 6,000 shares of Dermira stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $8.77, for a total transaction of $52,620.00. Following the completion of the transaction, the director now owns 11,051 shares of the company’s stock, valued at approximately $96,917.27. The disclosure for this sale can be found here. Insiders own 12.40% of the company’s stock.

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Dermira by 10.2% in the second quarter. Vanguard Group Inc. now owns 2,333,482 shares of the biopharmaceutical company’s stock valued at $22,308,000 after acquiring an additional 216,449 shares during the last quarter. Aperio Group LLC raised its position in Dermira by 24.4% in the 2nd quarter. Aperio Group LLC now owns 14,690 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 2,878 shares during the last quarter. JPMorgan Chase & Co. raised its position in Dermira by 76.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 782,223 shares of the biopharmaceutical company’s stock worth $7,025,000 after purchasing an additional 338,828 shares during the last quarter. Earnest Partners LLC raised its position in Dermira by 7.7% in the 2nd quarter. Earnest Partners LLC now owns 586,560 shares of the biopharmaceutical company’s stock worth $5,608,000 after purchasing an additional 42,060 shares during the last quarter. Finally, BB&T Securities LLC raised its position in Dermira by 27.2% in the 2nd quarter. BB&T Securities LLC now owns 28,560 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 6,110 shares during the last quarter. Institutional investors own 94.34% of the company’s stock.

About Dermira (NASDAQ:DERM)

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Recommended Story: Cash Asset Ratio

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.